NeuroEM Therapeutics Secures $5M Series A to Drive the Digital Biomarker Revolution in Neurology

NeuroEM Therapeutics is thrilled to announce that we have successfully raised $5,000,000 in our latest funding round—a significant milestone that propels our innovative mission forward. At NeuroEM Therapeutics, we are reimagining the way neurological conditions are diagnosed, treated, and monitored, harnessing the power of mathematical modelling to create novel digital biomarkers. Our breakthrough product, BioEP, represents our first clinical indication and is a pioneering digital biomarker designed specifically for epilepsy. By analyzing background EEG data through advanced mathematical models, BioEP provides an unprecedented risk score that predicts the likelihood of seizures, thereby supporting critical clinical diagnostic and prognostic decisions in epilepsy care. This influx of capital will be strategically invested to accelerate the expansion and refinement of our digital biomarker platform, ensuring that BioEP meets the evolving needs of clinicians and patients alike. Our approach is driven by the belief that digital biomarkers have the potential to transform neurological healthcare—from early diagnosis and risk stratification to personalized treatment strategies—ushering in a more proactive and anticipatory model of care. With this funding, NeuroEM Therapeutics is poised to enhance our research and development efforts, foster strategic partnerships with neurology centers, and navigate the regulatory pathways necessary to bring our next-generation diagnostics to market. We remain steadfast in our commitment to revolutionizing neurological healthcare with technology that not only anticipates clinical needs but also improves lives. As we embark on this exciting chapter, we extend our deepest gratitude to our investors and supporters, whose belief in our vision is helping us pave the way for a future where neurological conditions are managed more effectively and compassionately.